Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sotrovimab
Pharma
NICE advises against Merck's Lagevrio, AZ's Evusheld, 3 others
Five key products used to combat COVID-19—including Merck’s Lagevrio and AstraZeneca’s Evusheld—could be rejected for government funding in the U.K.
Kevin Dunleavy
Nov 16, 2022 10:43am
AZ gets key blessing in EU for Evusheld to treat COVID patients
Sep 16, 2022 10:50am
J&J-Legend, Junshi, Vir-WuXi and more—Fierce Pharma Asia
May 27, 2022 9:53am
Vir, WuXi terminate COVID antibody pact
May 23, 2022 8:35am
GSK, Vir's COVID antibody put on ice as BA.2 variant takes hold
Apr 5, 2022 3:42pm
With mAbs ineffective vs. subvariant, FDA limits GSK/Vir drug
Feb 24, 2022 9:35am
